Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 150.34M P/E - EPS this Y 16.90% Ern Qtrly Grth -
Income -101.35M Forward P/E -1.35 EPS next Y -6.50% 50D Avg Chg -17.00%
Sales 409k PEG - EPS past 5Y - 200D Avg Chg -64.00%
Dividend N/A Price/Book 0.90 EPS next 5Y - 52W High Chg -87.00%
Recommedations 2.10 Quick Ratio 11.08 Shares Outstanding 71.07M 52W Low Chg 3.00%
Insider Own 0.80% ROA -34.10% Shares Float 70.54M Beta 0.07
Inst Own 60.90% ROE -63.29% Shares Shorted/Prior 21.87M/21.70M Price 3.05
Gross Margin - Profit Margin - Avg. Volume 1,814,804 Target Price 20.57
Oper. Margin -534,900.00% Earnings Date Nov 5 Volume 986,970 Change -3.79%
About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc. News
12/19/24 Altimmune Added to Nasdaq Biotechnology Index
12/02/24 Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
11/26/24 Altimmune to Participate at Two Upcoming Investor Conferences
11/15/24 Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
11/14/24 Altimmune Third Quarter 2024 Earnings: Beats Expectations
11/12/24 Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/11/24 Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/11/24 Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
11/07/24 Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
11/04/24 Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
10/15/24 Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
10/01/24 Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
09/30/24 Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
09/10/24 CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
09/10/24 Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
09/03/24 Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
08/10/24 Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24 Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
08/07/24 CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
08/01/24 With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing
ALT Chatroom

User Image GreenEnergy2022 Posted - 49 minutes from now

$ALT

User Image GreenEnergy2022 Posted - 36 minutes from now

$ALT

User Image Cryptobearcat Posted - 2 hours ago

$ALT Can anyone confirms if we will or will not attend the JPM healthcare conference? and if for example, VKTX, TERN or structure will be attending?

User Image GSCCPA Posted - 3 hours ago

$ALT What day will $ALT HIT? Who knows what song is being sung here?

User Image Lazarus2024 Posted - 5 hours ago

$ALT GLP-1s are going to be the wonder drugs of the 21st century! They all are going to be blockbusters! https://apple.news/Ahe9Il4AySeGYusSkyLxR1A

User Image Szepen Posted - 5 hours ago

$ALT @Diapers_Tequila These shares will remain in the short-float mostly bc ETFs that tracks NBI will lend most of their shares to the shorties...this is business as usual for fund managers...

User Image BioRich Posted - 6 hours ago

@27Amberjack get used to it. That's all this is. $ALT is basically a penny stock with questionable data and presentations. Heavy blind support by optimistic get rich quick ALTers draws and attractive target for manipulators. Company hasn't controlled this stock for a bit.

User Image RoyMunson69 Posted - 6 hours ago

$ALT Altards never figured out how to take gains

User Image Stash_Cash Posted - 6 hours ago

$ALT new shareholder here…had $10 puts assigned to me. On board for the ride!

User Image D0C_H0LLIDAY Posted - 7 hours ago

$ALT (This scenario is not feasible if negotiations for a BO or partnership are being formalized at this point) However... Assuming there isn't at least an implicit agreement in place with BP, if Garg came out and said, "We are focusing solely on getting approval for MASH. Until WE receive a call from BP to bankroll velocity, we intend on proceeding full throttle with MASH and taking significant market share from Madrigal, and subsequently, first gen GLPS from off label scripts." "Since the co-morbidities Pemvidutide addresses are either byproducts of MASH, or precursors to MASH, we intend on profiting heavily from off label usage once the FDA has approved us for MASH, signifying a holistic approach to the health of our future clientele." A statement like this would give the market clarity and be healthy for share price imo.

User Image RO_LEX Posted - 8 hours ago

$ALT See you Monday!

User Image Filthycash7 Posted - 8 hours ago

$ALT I feel like the alt squad is a big family. We’ve been through ups and downs(literally) and I find it cool that we’re all still here and communicate almost daily. I truly enjoy sharing knowledge/incite, joking, and of course shitting on the bears with you guys haha The patience we’ve shown is going to pay off in a big way and I’m so excited for what the future holds for us. I wouldn’t want to do it with another group of bulls! I hope everyone enjoys the holidays!!!❤️

User Image damasta Posted - 9 hours ago

$ALT

User Image JoeDirty Posted - 9 hours ago

$ALT Still long and strong here- but picked up some $VKTX shares today due to the recent haircut. Vikings cash pile makes it an attractive Buyout candidate now- while Alt continues to deal with this short nemesis the stock simply cannot move. Just positioning myself to take advantage of the coming Pharma buying season. If Alt gets the call I’m more than covered, my Viking position is only 1/10 of my ALT position. Good luck to all.

User Image Jacked_Nicholson Posted - 9 hours ago

$ALT Good night and Happy Holidays!

User Image CallThemOut Posted - 9 hours ago

$ALT There is a reason, but fluff can be sold to shareholders. Does a shopkeeper put out the best & freshest stock on the shelf first? Or does he sell all the junk first and hold on to the good stuff for later? Grasso is loaded with inventory and ready to bump it up, rest of idiots haven't been given green light by the puppeteer yet.

User Image namv Posted - 10 hours ago

@Addairbob @Diapers_Tequila for real… heavy buying before the weekend? Something up for Monday? $ALT

User Image 7Billiards Posted - 10 hours ago

$ALT gonna fuck off for a week. See you all soon. Merry Christmas 💪💪💎

User Image Igobothways Posted - 11 hours ago

$ALT looks like with the MC that NVO lost today that the market values an early stage weight loss drug at $70-100 Billion.

User Image Jacked_Nicholson Posted - 12 hours ago

$ALT @RoidRagingBull is that what you were looking for?

User Image Lazarus2024 Posted - 12 hours ago

I think it’s the company that is trying to buy $ALT

User Image Super_Pemvidutarded_Ape Posted - 12 hours ago

$ALT how the fuck am I waiting for the market to open Monday again? I need someone to men in black me do I forget I even know the stock market exists and they can come get me when this hits $38 and I pocket my half million net.

User Image Lazarus2024 Posted - 12 hours ago

$ALT There has to be somebody bigger than Kerrisdale manipulating this PPS

User Image RoidRagingBull Posted - 12 hours ago

$ALT @Jacked_Nicholson had a great list of possible indications/NDA’s! Please repost when you can Jack!

User Image RoidRagingBull Posted - 12 hours ago

@HKDUP1987 @MAG2TROL @Stocktwits $ALT $ALT Watching Altimmune, Inc. (ALT) has a short interest of 23.43 million shares, which is about 32.94% of its float. The short interest ratio is 7.7, meaning it would take approximately 7.7 days of average trading volume to cover all short positions. 1 3

User Image GSCCPA Posted - 12 hours ago

$ALT I just got back from fishing, and as I posted this morning, I put a $7.90 $ALT buy order in at 7am, that did not execute, good and bad news, weather was great, 64 at beach, air & water, only caught 1 rat red, bad news, and I see that $ALT hit $8.75 with nice volume today! High Five!! Wait til Short Squeeze Monday

User Image YouVSYou Posted - 13 hours ago

$ALT $HIMS $LLY $NVO $TERN

User Image YouVSYou Posted - 13 hours ago

$hims the GLP 1 shortage is over Now what $tern $nvo $alt $lly

User Image Mikeiavelli Posted - 13 hours ago

$ALT I wonder if some of that large order outflow were mega shorts covering

User Image MarkeTimer Posted - 13 hours ago

$ALT Grasso on CNBC teed it up, but didn't ask the follow-up question. Dumb ass.

Analyst Ratings
B. Riley Securities Buy Aug 12, 24
B. Riley Securities Buy Jun 25, 24
Piper Sandler Overweight Jun 21, 24
HC Wainwright & Co. Buy May 14, 24
JMP Securities Market Outperform May 10, 24
Guggenheim Neutral Apr 29, 24
HC Wainwright & Co. Buy Apr 1, 24
B. Riley Securities Buy Mar 28, 24
B. Riley Securities Buy Feb 13, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Drutz David Director Director Aug 15 Buy 2.875 300 862 29,785 08/15/23
GILL JOHN Director Director Aug 12 Sell 15.00 2,714 40,710 2,771 07/06/23
Drutz David Director Director Mar 23 Buy 4.27 9,000 38,430 29,484 03/27/23
Eisenstadt Richard I Chief Financial Offi.. Chief Financial Officer Mar 24 Buy 4.314 10,000 43,140 22,010 03/24/23
Harris Matthew Scott Chief Medical Office.. Chief Medical Officer Mar 23 Buy 4.22 10,000 42,200 33,311 03/23/23
Garg Vipin K President and CEO President and CEO Aug 12 Sell 15.0593 15,000 225,890 259,804 08/12/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jul 01 Option 2.83 27,769 78,586 18,487 07/05/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jul 01 Sell 12 37,164 445,968 8,305 07/05/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jun 27 Option 2.26 37,352 84,416 55,052 06/28/22
Roberts M Scot Chief Scientific Off.. Chief Scientific Officer Jun 27 Sell 12 37,352 448,224 17,700 06/28/22
Drutz David Director Director Jun 15 Buy 8.00 1,000 8,000 20,012 06/16/22
Drutz David Director Director May 24 Buy 4.50 1,200 5,400 19,012 05/25/22
Harris Matthew Scott Chief Medical Office.. Chief Medical Officer Feb 28 Option 1.92 30,000 57,600 41,545 03/02/22
Harris Matthew Scott Chief Medical Office.. Chief Medical Officer Feb 28 Sell 7.52 30,000 225,600 11,545 03/02/22
Drutz David Director Director Jan 25 Option 2.4 70 168 17,882 01/26/22
Hodges Philip Director Director Dec 02 Sell 12.77 3,727 47,594 12/02/20